SASSARI, Italy & PRINCETON, N.J.--(BUSINESS WIRE)--ViroStatics, a US/Italian biopharmaceutical company developing innovative immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data from a randomized, dose-ranging trial of VS411, the Company’s novel combination product for treating HIV/AIDS, during the XVII International AIDS Conference this week in Vienna, Austria.
